狄诺塞麦治疗骨转移效果如何呢？

How effective is the treatment of bone metastases? Let's find out through some experiments.

A randomized, placebo-controlled phase III clinical trial, DEFEND (Denosumab Fortifies Bone Density), evaluated the effect of denosumab in preventing osteoporosis in postmenopausal women. The average age of the subjects was 59.4 years old, and the spine T-scores were between -1.0 and -2.5 (mean was -1.61). They were randomly divided into a treatment group (denosumab 60 mg subcutaneous injection, once every 6 months, n=166) or a placebo group (n=166). All patients were supplemented with 1000 mg of calcium every day, and 25-hydroxyvitamin D was passed through the subjects' plasma. The level determines whether vitamin D supplementation is needed. The main evaluation index is the change in spinal BMD measured by dual energy X-ray absorptiometry (DXA) compared with the baseline level.

The results showed that after 24 months, denosumab significantly increased spinal BMD values compared with placebo (a 6.5% increase in the treatment group versus a 0.6% decrease in the placebo group). In addition, the BMD values ​​of all tested parts such as the hip bone and distal radius in the treatment group increased significantly. At the same time, markers of bone resorption and formation were significantly reduced. The overall incidence of adverse reactions in the treatment group was similar to that in the placebo group during the observation period.

It has achieved good results in the treatment of various diseases, and has also obtained orphan drug qualifications for the treatment of giant cell tumor of bone and malignant hypercalcemia. And from the above-mentioned trials, we can also clearly see that denosumab plays a positive role in the treatment of bone metastases, and the effect is significant.